Ropes & Gray has advised Pfizer on its strategic investment in and collaboration with innovative UK-based biotechnology company CellCentric, which includes $25m to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer.
Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific haematological malignancies, through its Pfizer Ignite offering.
Pfizer Ignite is a new end-to-end service for biotech companies with high potential early science that leverages Pfizer’s significant R&D capabilities, scale and expertise to accelerate the development of breakthrough therapies.
The Ropes & Gray team was led by venture capital and emerging companies partner Brad Flint and strategic transactions counsel David Dowling with support from strategic transactions associate Sam Wolfe-Murray, life sciences associates Rajarshi Banerjee, Kyle Connors, Danielle Heinlein and Corinne Maguire, tax partners Andrew Howard and David Saltzman, senior attorney Ariella Mutchler and associate Sophie Waters, life sciences regulatory associate Hannah Kerr-Peterson and data, privacy & cybersecurity associate Edward Machin.
